非小细胞肺癌的驱动基因及其临床意义

Driver Genes and Its Clinical Significance in Non-small Cell Lung Cancer

随着分子生物技术的发展和药物研发模式的转变,根据肺癌驱动基因突变谱指导分子靶向治疗已逐渐成为现实。明确各驱动基因在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的发生率及是否存在优势人群,对临床实践具有重要指导意义。本文将对NSCLC中主要驱动基因的一般特点、人群特征及临床意义进行综述。

With the development of molecular biology technology and the transforming patterns of drug research, guiding molecular targeted therapy according to the drive gene mutation spectrum in lung cancer has gradually become a reality. Deifnition of the mutation incidence and whether existing advantage population groups in non-small cell lung cancer （NSCLC） have important guiding signiifcance in clinical practice. hTe purpose of this paper will draw a summary on the gen-eral characteristics, demographic features and clinical signiifcance of driver genes in NSCLC.